ANIX stock forecast, quote, news & analysis
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology... Show more
Why Anixa Biosciences (ANIX) Stock Is Up +17.6% in the Last 30 Days
Key Takeaways
- ANIX shares rose roughly 17.6% over the last 30 days, moving from a close of $2.79 on September 28 to $3.28 on October 27.
- Most of the advance came from a roughly 12% single-session jump on October 27 after analysts reiterated bullish ratings and price targets.
- Over the last quarter, the stock remains down about 6.8%, reflecting a September pullback followed by a late-October recovery.
- Anixa Biosciences is a clinical-stage oncology company developing a breast cancer vaccine and a CAR-T therapy for ovarian cancer.
- Recent catalysts include analyst reiterations, insider purchases, and steady progress across its clinical programs.
- Investors can find additional detail on Price Targets, Earnings, and Forecast pages for a fuller view of the ticker.
- Explore Trending AI Robots to see curated, top-performing AI trading bots.
Anixa Biosciences (ANIX) Company Overview and Market Position
Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Headquartered in San Jose, California, the company operates in two core areas: therapeutics and vaccines. Its lead therapeutic candidate, lira-cel (liraltagene autoleucel), is a chimeric endocrine receptor T-cell (CER-T) therapy, a novel form of CAR-T technology being studied for ovarian cancer in partnership with Moffitt Cancer Center. The company is also advancing a breast cancer vaccine designed to target the protein alpha-lactalbumin, developed in collaboration with the Cleveland Clinic, and maintains a broader vaccine discovery program aimed at additional cancers such as lung, colon, and prostate.
Because Anixa is pre-revenue and unprofitable, investors follow the stock primarily for clinical trial milestones, patent activity, and the progress of its research partnerships rather than conventional earnings metrics. This makes ANIX a higher-risk, catalyst-driven investment that can experience sharp moves on relatively modest news flow.
Anixa Biosciences (ANIX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ANIX advanced approximately 17.6%, climbing from $2.79 to $3.28. The move was concentrated in the final stretch of the period, with a sharp single-day gain on October 27 that lifted the stock from $2.93 to $3.28.
The longer three-month view tells a more nuanced story. The stock traded near $3.52 in late July before sliding through August and September to intraday lows around $2.56–$2.61, then staging a partial recovery in late October. Measured from the late-July close, shares remain down roughly 6.8% over the quarter, putting the recent 30-day rally in the context of a broader multi-month consolidation rather than a one-way trend. The stock sits well within its 52-week range of $2.32 to $5.46.
What Drove ANIX Stock Price in the Last 30 Days
The most significant driver of the 30-day advance was a wave of bullish analyst activity in late October. On October 27, Maxim Group maintained a Buy rating with a $14 price target, while H.C. Wainwright reiterated a Buy rating with a $6 target, contributing to the roughly 12% single-session gain. The renewed analyst attention refocused investor interest on the company's clinical pipeline.
The move was also supported by insider confidence. Filings disclosed open-market purchases by company executives and directors, including Chairman and CEO Amit Kumar, which can signal management's conviction in the company's prospects. On the clinical front, Anixa continued to advance its programs, reporting the administration of a second dose in its ovarian cancer CAR-T trial, submitting a protocol amendment for that study, and unveiling its Phase 2 study plan for the breast cancer vaccine. Together, these developments reinforced the narrative of steady pipeline execution that underpinned the rally.
What Drove ANIX Stock Performance Over the Last Quarter
The quarterly picture was shaped by a mix of encouraging clinical data and broader volatility. Earlier in the period, Anixa reported that its Phase 1 breast cancer vaccine study met its primary endpoints, demonstrating safety and generating protocol-defined immune responses in a majority of participants. The company also shared positive survival observations from its lira-cel ovarian cancer program and announced additional patent allowances in the United States and abroad.
Despite these milestones, the stock drifted lower through the summer and early autumn as investors weighed the typical risks facing a pre-revenue biotech, including cash runway and the timeline to later-stage trials. The late-October analyst reiterations and insider buying helped reverse that slide, leaving the stock lower on the quarter but on an upward trajectory into the period's close.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from a much larger universe of automated strategies covering thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a focused view of strategies that have recently demonstrated strength. The bots vary widely in approach, timeframe, and performance metrics, so visitors can compare different methodologies and find systems that align with their own trading style. Exploring this section can offer a useful starting point for those interested in data-driven, automated trading approaches.
ANIX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to monitor several key factors. Clinical updates remain central, including further data from the Phase 1 ovarian cancer CAR-T study and progress toward the planned Phase 2 breast cancer vaccine trial. Patent issuances and partnership developments with Moffitt Cancer Center and Cleveland Clinic also carry the potential to influence sentiment. On the financial side, Anixa's cash position and burn rate will remain in focus for a pre-revenue company, as will any capital-raising activity. Analyst expectations, currently reflecting a generally bullish stance with price targets ranging from $6 to $14, may shift as new clinical and regulatory information emerges. As with any clinical-stage biotechnology company, trial outcomes and regulatory decisions represent the most material sources of risk and opportunity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ANIX sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ANIX moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ANIX moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 53 cases where ANIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANIX as a result. In 88 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
ANIX broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ANIX just turned positive on October 22, 2026. Looking at past instances where ANIX's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.
ANIX moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ANIX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +9.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIX advanced for three days, in 180 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. ANIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.627) is normal, around the industry mean (3.498). P/E Ratio (-9.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (384.615) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of non-invasive blood tests for the early detection of solid tumor based cancers
Industry Biotechnology